Growth Metrics

Protalix BioTherapeutics (PLX) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $2.4 million.

  • Protalix BioTherapeutics' Profit After Tax fell 2722.5% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 15615.24%. This contributed to the annual value of $2.9 million for FY2024, which is 6472.57% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Profit After Tax stood at $2.4 million for Q3 2025, which was down 2722.5% from $164000.0 recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Profit After Tax registered a high of $19.3 million during Q2 2023, and its lowest value of -$11.2 million during Q2 2021.
  • Over the past 5 years, Protalix BioTherapeutics' median Profit After Tax value was -$3.6 million (recorded in 2022), while the average stood at -$1.7 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 219654.09% in 2021, then surged by 46256.09% in 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Profit After Tax (Quarter) stood at -$6.7 million in 2021, then soared by 43.9% to -$3.7 million in 2022, then crashed by 61.6% to -$6.0 million in 2023, then surged by 207.45% to $6.5 million in 2024, then tumbled by 63.74% to $2.4 million in 2025.
  • Its Profit After Tax was $2.4 million in Q3 2025, compared to $164000.0 in Q2 2025 and -$3.6 million in Q1 2025.